THIS REPORT FOCUSES ON A POST HOC EXPLORATORY ANALYSIS OF THE PHASE 3 KEYNOTE-204 STUDY COMPARING PEMBROLIZUMAB AND BRENTUXIMAB VEDOTIN BY NUMBER OF PRIOR LINES OF THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL). OF 304 PARTICIPANTS RANDOMLY ASSIGNED (1: 1) to pembrolizumab or brentuximab vedotin, 55 received 1 prior therapy and 249 received ≥2. For 1 prior therapy, median progression-free survival (PFS) at primary analysis (including clinical imaging data after autologous stem cell transplant [auto-SCT]) was 16.4 months with pembrolizumab and 8.4 months with brentuximab vedotin; objective response rate (ORR) was 66.7% and 53.6%. For ≥2 prior therapies, median PFS at primary analysis was 12.6 months with pembrolizumab and 8.2 months with brentuximab vedotin; ORR was 65.3% and 54.4%. Pembrolizumab improved PFS and ORR versus brentuximab vedotin regardless of prior therapies. Data suggest pembrolizumab may be a promising second-line therapy for participants with R/R cHL ineligible for auto-SCT.

CLINICAL TRIAL INFORMATION: ClinicalTrials.gov, NCT02684292.